NanoLogix Inc (NNLX)

[All City Baby]

Company Updates


June 5, 2017

Reception of the NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli Presented at the American Society for Microbiology (ASM Microbe) Annual meeting

Novel Rapid Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7

Jonathan Faro, MD, PhD and Sebastian Faro, MD, PhD, medical researchers presenting the technology poster at the ASM Annual meeting in New Orleans this past weekend stated:

"ASM Microbe was a very stimulating meeting. We enjoyed meeting many investigators and the engaging discussions that followed. Of the many rapid ID tests either on the market or the many more that presented and will soon be available, our assay is the most unique, and has the ability to provide the greatest limit of detection while simultaneously determining antibiotic susceptibility."

Further information from NanoLogix metrics monitoring indicated interest from at least two major laboratories.

The N-Assay is currently undergoing development for rapid detection of Urinary Tract Infections (UTI) and we anticipate the N-Assay to be debuted soon as the definitive UTI test for speed, accuracy, and sensitivity.

Two published examples of the N-Assay and its performance can be accessed through the following links:

https://www.hindawi.com/journals/idog/2016/5293034/

http://nanologix.com/news/poster-e-coli-0157.pdf

The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B
Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.


June 2, 2017

Update: NanoLogix N-Assay Bacteria Diagnostic Technology Poster for E. coli To Be Presented Tomorrow at the American Society for Microbiology (ASM) in New Orleans

Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7

This poster presentation will occur Saturday, June 3rd from 12:15 to 14:15 at position #456 in the category of Diagnostic Bacteriology III.

http://nanologix.com/news/poster-e-coli-0157.pdf

The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.


June 1, 2017

NanoLogix TB Detection Technology Use on Africa Project Increases

NanoLogix is pleased to announce that this week they shipped a new order for their TB Diagnostic test kits for use on an Africa research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from US and foreign Government agencies.

This is the third order since April on the Africa Project. NanoLogix was informed that in addition to the two sizes of kits sold in this order (150 mm and 100 mm), NanoLogix should prepare to supply two additional sizes of TB detection kits and also to significantly scale up TB kit production to satisfy projected needs.

For reference from an earlier update: "The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:

https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html

Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal."


May 19, 2017

NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli limited abstract

Novel Immunoassay for Simultaneous Identification and Determination of Antibiotic Susceptibility of E. coli O157:H7

Novel Immunoassay for E coli O157:H7

Researchers: Classified until June 2017

Introduction: E. coli O157:H7 is associated with enterohemorrhagic infections, and is a concern for healthcare providers, food-handlers, and daycare providers. Rapid identification of this pathogen is critical in cases of outbreaks, and empirical treatment with broad-spectrum antibiotics may lead to more severe disease. We have developed an assay that allows for the simultaneous identification of E. coli O157:H7 and determination of its antibiotic susceptibility.

Methods: N-ASSAY

Methods Details Classified until June 2017

Results: O157:H7 was detected at and above 10^6 bacteria/ml following a 30-minute incubation, with no interference by other tested bacteria. By increasing the incubation time to 6 hours, the sensitivity of the test increased to 10^1 bacteria/ml. In addition, incubation with ceftriaxone during this six-hour time period showed inhibition of growth.

Summary: This assay allows for the rapid detection of a high inoculum of E. coli O157:H7, and sensitivity is increased following a six-hour incubation. Importantly, antibiotic susceptibility may be determined during this six-hour incubation.

The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.


May 8, 2017

Additional TB Test Kits ordered for Third World Gates Foundation Project

NanoLogix is pleased to announce that they have just (8 May 2017) received a new order for double the amount of their TB Diagnostic test kits delivered in April for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.

Since the request from the project representative stated that it is imperative the kits be delivered as soon as possible, NanoLogix is shipping the kits for Wednesday delivery. While the total sales amounts for the TB kits is in the thousands of dollars, Nanologix hopes the sales for use in this and other related TB projects will grow significantly.

The technology used in the NanoLogix TB Test Kit is our BNP sandwiched-membrane technology. The use of the TB kit is to provide evidence of the presence of active (live) TB bacteria in a patient sample in 4-6 days rather than 3-5 weeks or more. The results from the NanoLogix TB tests are then processed through PCR (DNA testing) and other means to further define the identity of the TB. The original research paper citing the detection results and potential of pairing the NanoLogix technology with other technologies is available through this link:

https://www.omicsonline.org/1948-5948/JMBT-04-147.digital/JMBT-04-147.html

Related to this work, NanoLogix has received a request to pursue development of an N-Assay modified ELISA for detection and identification of TB. We will be doing so upon receipt of sufficient funding for that goal.

In other news, patent work on either/both FlatPack and N-Assay patent applications has reached the stage where final examinations have been requested in Mexico, Canada, South Korea, and Brazil. Notification of FlatPack Patent Grant was received last week from Chile.


May 4, 2017

TB test Kits for use in Third World Gates Foundation Project

NanoLogix is pleased to elaborate further on an item of note from last month's announcement regarding shipment of TB Diagnostic kits to a Third World Research Project. The Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by the National Institutes of Health, (NIH) the National Institute of Allergies and Infectious Diseases (NIAID) and the Bill and Melinda Gates Foundation, with other funding from foreign Government agencies.

Three reasons exist for this announcement. The first is to inform the public that whenever we released previous news where we were either named as being associated in research and development by an entity such as the US EPA or the University of Texas Health Science Center in Houston, or were cited in a research paper dealing with our technology by Battelle Biomedical Research Center in Ohio, those entities were all harassed by persons claiming to be NanoLogix shareholders who demanded to know the nature of the business relationships between the entities and NanoLogix and who asked for insider information regarding the status of the ongoing research. Those harassing efforts nearly destroyed the ongoing business relationships NanoLogix was truly privileged to have with those organizations. In this case anyone pursuing the same tact will come up against some very non-receptive forces.

The second is to demonstrate that we at NanoLogix had a goal, and that was to develop and provide to the world, diagnostic and research technologies that are premier and second to none, to create jobs in the rust belt area of northeast Ohio where the mindset of the area is steel mills, auto manufacturing, and low tech service jobs.

The third is to call attention to the facts that we, being a penny stock company, are considered the lowest of the low for investment. We are ignored by brokerages, especially ignored by the local media, and scorned by the investment community in general. Oddly enough, as ignored as we've been, we have still developed customized versions of our new N-Assay modified ELISA rapid bacteria diagnostic for one of the World's largest medical technology companies (under a very strong non-disclosure agreement), worked with the US EPA on developing tests for drinking and source waters, and had our technology presented as the fastest, most accurate and sensitive bacteria diagnostic test in the world. In addition, we've sold large numbers of proprietary packed FlatPacked petri plates in the USA and around the world for use in everything from simple quality control, food processing monitoring, soil testing, cosmetics and personal care products testing, environmental testing for post-flood contamination, water quality analysis, biodefense (we think, but classified), university research, and tens of thousands of users through Amazon and EBay for varied uses.

...and now we've sold TB diagnostics for use on a project funded by whom...?

Our share price and company are under attack by sick manipulators who only hurt dedicated shareholders. We as a company will survive and prosper.

We will expand our facilities as soon as feasible for increased FlatPack and N-Assay production, and are exploring relocating to a different state where we can be considered as bringing a benefit to the area.


Apr. 28, 2017

NanoLogix N-Assay Bacteria Diagnostic Technology for Rare Deinococcus Bacteria to be presented at AACC Annual Meeting in San Diego:

NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, recently configured for detection and identification of a rare Deinococcus bacteria species will be presented in poster format at the American Association for Clinical Chemistry (AACC) 69th Annual Scientific Meeting and Clinical Lab Expo, to be held at the San Diego Convention Center in San Diego, California from July 30th through August 3rd, 2017. Dr. Jonathan Faro, MD, PhD and others associated with the development will be present for the poster session.

NanoLogix personnel are exploring the potential of staffing an exhibit booth at the event to display both the new modified-ELISA N-Assay diagnostic kit and also the FlatPack extended shelf life technology for petri plates.

The N-Assay Diagnostic furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus.

The published research results may be accessed through this link:

http://dx.doi.org/10.1155/2016/5293034

The AACC Deinococcus poster presentation illustrates how the N-Assay reduces the detection and identification times from roughly two weeks to a few days, with improved sensitivities over any other known test method.

Further information as to poster display and potential exhibit booth location will be made available in the near future when supplied to us by the AACC. Currently, general information for the event may be found by following this link:

https://www.aacc.org/meetings-and-events/2017-annual-meeting/clinical-lab-expo

The N-Assay Diagnostic for eColi will also be presented at the ASM Microbe 2017 in New Orleans June 1-5. Information for that event is available here:

https://www.asm.org/index.php/asm-microbe-2017


Apr. 4, 2017

NanoLogix has shipped TB test Kits for use in Third World Project

NanoLogix is pleased to announce items of note that have occurred this week. The first is that the Company has sold and shipped their TB Diagnostic test kits for use on a Third World research project funded by multiple US Federal and foreign Government agencies and a large international philanthropic organization. Once the project results are published we will be at liberty to elaborate further. The second item is that the Company today received the largest single delivery to date of petri plates for continued production of prepoured agar-filled FlatPacks, taking delivery of 150,000 sterilized petri plates.


Mar. 16, 2017

NanoLogix N-Assay Bacteria Diagnostic Technology for E. coli to be presented at June ASM Annual Meeting in New Orleans:

NanoLogix is pleased to announce that the N-Assay Bacteria Diagnostic, newly configured for E. coli will be presented in poster format at the American Society for Microbiology ASM Microbe 2017 to be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana from June 1st through 5th. Dr. Sebastian Faro, MD, PhD and others associated with the development will be present for the poster session.

NanoLogix personnel are planning to staff an exhibit booth at the event to display both the Company-offered FlatPack for petri plates and the new N-Assay diagnostic. The FlatPack technology is becoming the premier petri plate storage method for those interested in long life room-temperature storage of prepared agar, with basic poured agars usable in as-new condition after 2-4 years of non-refrigerated storage. The NanoLogix FlatPack is available through www.nanologix.com and also on Amazon.com through two companies --- Evviva Scientific and Diamante Scientific.

The N-Assay furnishes the ability to detect and identify bacteria and other microorganisms in record time and provide a nearly simultaneous determination of their antibiotic resistance with unparalleled sensitivity. It was unveiled at the 2016 Central Association of Obstetricians and Gynecologists Annual Meeting in October, 2016, winning the Judges’ Choice Award for poster presentation of: Development of a Novel Antibody-Based Assay for Simultaneous Identification of a Pathogen and Determination of its Antimicrobial Susceptibility. That presentation demonstrated the capability of the N-Assay for use against Group B Streptococcus, Gonorrhea, and Enterococcus. The E. coli development is an additional tool in the battle against both non-resistant and antibiotic-resistant bacteria.

Further information as to poster display and exhibit booth location will be made available in the near future when supplied to us by the ASM.


Mar. 2, 2017

NanoLogix is pleased to present a further update on the N-Assay Bacteria Diagnostic Technology:

After testing with customized N-Assay kits we supplied in January, the large medical technology client referenced in earlier updates has requested quotes from NanoLogix for expansion and further development using the N-Assay technology to detect additional bacteria species and genera.

Nanologix personnel and associates are excited to work with one of the World's largest medical companies on these N-Assay customizations. Due to a confidentiality agreement with our client, we cannot currently disclose the client identity.

There still remains the step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay. Personnel at a number of hospitals are reviewing potential study participation.


Jan. 9, 2017

NanoLogix is pleased to present a brief update on the N-Assay Bacteria Diagnostic Technology:

The N-Assay takes its place on our FDA medical device listing:

http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=469637&lpcd=LIB

There is the remaining step of an independent time and sensitivity study for NanoLogix prior to marketing and sales for clinical use of the N-Assay.

NanoLogix has supplied all of the initially contracted and customized N-Assay kits to our multi-billion dollar medical technology client and we are awaiting results of their global testing.


Dec. 20, 2016

NanoLogix is pleased to announce the following Update:

The Company has narrowed its selection of buildings to use as a larger production facility in northeast Ohio. Two existing buildings are now under consideration to house NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic. The projected expenditure for establishing N-Assay production and increasing petri plate production is roughly $900,000 for production equipment, $125,000 for the construction of two separate 70' X 30' production cleanrooms, and $40,000 for additional equipment such as forklifts.

This expansion is projected to result in market share increase for petri plate sales due to markedly improved economies of scale, and position NanoLogix with a significant production capability for the new N-Assay modified ELISA comprehensive bacteria diagnostic kit. The Company expects the expansion will result in ten additional jobs starting with the delivery and setup of the production equipment in 2017 and another ten positions upon expansion of N-Assay sales.

Over the coming six months we expect to finance the expansion through a combination of increasing revenue from sales of both product lines and fundraising through our current SEC Regulation D, Rule 506 offering for private placement sales of shares.

Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix.

The Company is preparing to seek licensees in Europe and Hong Kong for production of FlatPack Petri Plates under the recent EU FlatPack patent approval.

In response to queries coming to our office regarding our customization of the N-Assay for a multibillion medical technology company: we have sold 600+ of the N-Assay to them and will be supplying more in addition to further customization for other bacteria in 2017. As our arrangement with the client is CONFIDENTIAL, we will not be releasing their name.

Merry Christmas from Carol, Debby, Kim, Travis, Bret and all


Dec. 6, 2016

NanoLogix is pleased to announce the following Update:

The Company is currently searching for a larger production facility in northeast Ohio. In the past three weeks NanoLogix management and production staff have viewed, toured, and measured four separate sites to ascertain site suitability for relocating and expanding NanoLogix production for both petri plates and for production of the new N-Assay ELISA-based rapid bacteria diagnostic.

The new sites being surveyed range from 10,000 square feet to 22,000 square feet, three to seven times the size of our current facility. All sites viewed offer additional square footage for further expansion as required.

NanoLogix is also in the process of specifying and ordering new equipment for the production of both petri plates and the new N-Assay.

The two petri plate filling machines that have been configured for order are both OnlineEngineering MultiDish Model 968 with ancillary equipment. The Model 968 is capable of filling 9,600 plates per hour, so the two machines should be capable of meeting production needs for the forseeable future. Further information on the equipment can be found at: www.online-engineering.com

The N-Assay equipment currently being researched and specified are automatic pippetting machines for application of antibodies, etc., to the ELISA plates used for this revolutionary rapid bacteria diagnostic technology.

The two technologies will be housed in separate modular cleanrooms in order to comply with specific FDA requirements for manufacturing of each product.

The projected timeline for delivery and assembly of modular cleanrooms, the OnlineEngineering equipment, and the automated pippetting machines is sometime in the second quarter of 2017, while configuration of whichever of the candidate sites is chosen is projected to begin in the first quarter of 2017.

Petri plate production is currently in Hubbard, Ohio, while N-Assay production is in Houston, Texas. N-Assay production in Ohio is projected to begin in the second quarter of 2017.


------------------------------------------------------------------------------------------------------------------------------


Updates are available by signing up for eNews on the company's homepage at nanologix.com.